Compare NUVL & BOKF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | BOKF |
|---|---|---|
| Founded | 2017 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.3B |
| IPO Year | 2021 | 2007 |
| Metric | NUVL | BOKF |
|---|---|---|
| Price | $99.24 | $125.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 10 |
| Target Price | ★ $135.33 | $127.10 |
| AVG Volume (30 Days) | ★ 443.1K | 296.7K |
| Earning Date | 01-01-0001 | 04-17-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | N/A | ★ 12.65 |
| EPS | N/A | ★ 9.17 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.56 |
| Revenue Next Year | $1,064.25 | $5.35 |
| P/E Ratio | ★ N/A | $14.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $85.08 |
| 52 Week High | $113.02 | $138.42 |
| Indicator | NUVL | BOKF |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 38.85 |
| Support Level | $98.65 | $103.22 |
| Resistance Level | $107.13 | $138.25 |
| Average True Range (ATR) | 4.05 | 3.37 |
| MACD | -0.31 | -0.92 |
| Stochastic Oscillator | 19.28 | 14.44 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
BOK Financial Corp is a financial institution in Oklahoma, and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services, including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking, and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.